Indian drug companies are poised to transform diabetes care with cost-effective generic versions of Empagliflozin as its patent expires. This move is expected to drastically reduce expenses and enhance availability for more than 10 crore diabetic patients. Leading the charge, Mankind Pharma and other companies will introduce the drug at a substantially lower price point, providing relief from financial strain while also boosting cardiovascular and renal health.